Transcarent has introduced a Transcarent bundled payment model for advanced cancer therapies. The model covers bispecific T-cell engager (BiTE) and CAR T therapies. The company announced the new payment approach on August 25. It will support therapies delivered through high-quality community providers.
The initiative further strengthens Transcarent’s industry-leading complex care Centers of Excellence (COE) capabilities. It also expands the company’s Cancer Care experience. Through this model, Transcarent bundled payment model aims to bring advanced cancer treatment closer to Members. At the same time, employers can gain greater predictability over oncology costs.
Advanced cancer treatments have opened great treatment opportunities for the patients. But these therapies face big challenges around access and affordability. There are a lot of breakthrough therapies that cost hundreds of thousands of dollars. Patients are often required to travel to specialized academic medical centers. This can create further challenges for patients and their caregivers. Complex referrals and prior authorization requirements can also be a barrier to treatment. Transcarent’s new approach tackles these concerns with bundled payment arrangements. These compacts involve high quality regional and community based providers.
Breakthrough cancer therapies shouldn’t require choosing between access and affordability. Transcarent’s new bundled payment model expands access to BiTE and CAR T therapies closer to home, with predictable costs and potential savings of up to $150,000.
“Advanced cancer therapies are changing what’s possible for patients, but they’re also creating new challenges for employers trying to manage costs and access,” said Snezana Mahon, PharmD, President of Transcarent. “This model gives employers more predictable costs while helping Members receive expert care closer to home without sacrificing quality.”
Transcarent Strengthens Community Cancer Care
The expansion strengthens Transcarent’s Centers of Excellence program. It also makes specialty cancer care easier to access and navigate. Additionally, the approach focuses on improving affordability for employers and Members. Regional and community providers can deliver coordinated care under bundled payment agreements.
Members can receive expert guidance throughout their treatment journey. Meanwhile, employers can gain greater visibility into treatment costs. BiTE and CAR T therapies treat several complex cancers and patient conditions. Therefore, treatment costs can differ considerably between individual cases. Transcarent connects Members with leading oncology providers across multiple care settings. These include academic medical centers and NCI-Designated Cancer Centers.
The network also includes high-quality community-based sites of care. These providers support complex cancer services across different treatment areas.Services include surgery, radiation, and infusions. The network now also supports CAR T and BiTE therapies. As a result, the Transcarent bundled payment model can improve access to advanced immunotherapies. Patients can receive quality treatment closer to their homes and support networks. The company said the approach offers potential savings of up to $150,000. This could help employers address the growing financial pressure associated with advanced oncology care.
“Expanding access to innovative therapies like BiTE and CAR T in high-quality community settings is a critical step towards more equitable cancer care,” said Karen Knudsen, MBA, PhD, past Chief Executive Officer of the American Cancer Society and Chair of Transcarent’s Cancer Care Advisory Board. “This model can reduce barriers to treatment while improving the experience for people and their families facing some of the most complex cancers.”
Oncology Nurse Navigators Support Members
Transcarent also provides dedicated support for Members receiving BiTE or CAR T therapies. These services operate through the company’s Cancer Care COE network. Members receive assistance from ACS LION™-certified Oncology Nurse Navigators (ONN). These specialists remain a consistent point of contact throughout the treatment process. Their support begins with the referral stage and continues through recovery. Furthermore, the ONN team helps Members and their families manage complex treatment journeys.
Navigators help coordinate care between providers. They also tell Members about the treatment choices available. They also identify and work to remove barriers to care. This support can help make the experience of treatment easier for patients and their families. The usual approach in treating advanced cancer involves a team of health care professionals. Dedicated navigation can thus facilitate a more efficient navigation of the patient through each stage. Transcarent bundled payment model is also partnering with national oncology practices. The collaborations are intended to expand access to more sophisticated therapies in community settings.
Transcarent and Vantris Expand Community Oncology Access
One of the company’s partners is Vantris Oncology. The organization manages oncology networks and supports value-based cancer care models. Vantris Oncology brings together community oncology practices and providers across the country. Its national infrastructure supports cancer care closer to patients’ communities. The partnership combines several capabilities to strengthen community-based cancer treatment. These include oncology infrastructure, integrated navigation, quality management, and value-based payments.
Together, the organizations aim to deliver high-quality cancer care through community settings. The model also supports access to advanced therapies closer to Members’ support networks. This approach can create a more consistent cancer care experience. It also aligns quality, accessibility, and affordability across the treatment journey.
“Cell therapies which harness the power of the immune system to destroy cancer cells are treatment breakthroughs which can dramatically improve the lives of people with cancer and autoimmune diseases. The science is amazing, but the problem is one of access and affordability,” said Edward Licitra, MD, PhD, CEO of Vantris Oncology. “Together, Transcarent and Vantris’ nationwide network of community practices can transform access to these life-saving therapies by making them available to patients wherever they live.“
Overall, the Transcarent bundled payment model strengthens the company’s approach to advanced cancer care. It combines payment innovation with community-based oncology services. The model also supports greater access to BiTE and CAR T therapies. At the same time, it gives employers a more predictable framework for managing oncology expenses.
By connecting Members with qualified providers, Transcarent is expanding treatment options. The company is also bringing advanced cancer therapies closer to where patients live. The initiative highlights the growing role of value-based cancer care. It also reflects increasing demand for accessible and affordable advanced oncology treatment. Through its COE network and community partnerships, Transcarent continues to expand complex care capabilities. The company’s latest payment model adds another layer to that strategy.
Explore Health Tech Insiders for the latest medical innovations and reliable strategic insights driving the future of technology-driven healthcare transformation.
News Source: Businesswire.com
